Please assess the completion status of the following clinical trial:

Trial Title: CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic multiple myeloma, ISS stages I-III, within 12 months of starting therapy.~* Completion of induction therapy with Very Good Partial Response (VGPR), or better, by International Myeloma Working Group (IMWG) criteria.~* Deemed eligible for ASCT by standard institutional criteria.~* Age ≥18 years.~* Documentation of CT7, MAGE-A3, or WT1 expression in the bone marrow and/or bone marrow aspirate.~Exclusion Criteria:~* Prior autologous or allogeneic SCT.~* Previous immunization against CT7, MAGE-A3, other cancer-testis antigens, or WT1.~* Known immunodeficiency, HIV positivity, hepatitis B, or hepatitis C.~* History of autoimmune disease (e.g., rheumatoid arthritis, SLE), other than vitiligo, diabetes, or treated thyroiditis, which are allowed.~* History of severe allergic reactions to vaccines or unknown allergens.~* Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first immunization.~* Lenalidomide-related toxicities before ASCT necessitating its discontinuation as part of treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 Vaccine (Type: EXPERIMENTAL): This is a prospective, two-arm phase I randomized trial. Patients will be accrued only from and treated at MSKCCand The Rockefeller University/Center for Clinical \& Translational Science . The study will assess autologous LCs presenting CT7, MAGE-A3, and WT1 after electroporation with CT7, MAGE-A3, and WT1 mRNA. Twenty patients will accrue to the study and ten will receive vaccines at 9x10\^6 LCs per dose (i.e., combination of 3x10\^6 CT7 mRNA-electroporated LCs + 3x10\^6 MAGE-A3 mRNA-electroporated LCs + 3x10\^6 WT1 mRNA-electroporated LCs) and another ten who will not receive any LC vaccines but will otherwise undergo identical cytoreduction, ASCT, and standard supportive care. At approximately 3 months after ASCT and as deemed clinically appropriate, patients will start lenalidomide maintenance therapy, which is now standard to delay disease progression.
- Arm 2 control (Type: ACTIVE_COMPARATOR): Patients receive standard of care treatment after autologous stem cell transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).